Erythrocyte-bound apolipoprotein B in atherosclerosis and mortality
Background: The binding of apolipoprotein (apo) B-containing lipoproteins to circulating erythrocytes (ery-apoB) is associated with a decreased prevalence of atherosclerosis. In this study, we evaluated ery-apoB as a possible prognostic factor in cardiovascular events and all-cause mortality, in a prospective cohort study. Materials and methods: Ery-apoB was measured by flow cytometry in subjects with and without cardiovascular disease (CVD). The primary endpoint was the cardiovascular event rate. Secondary endpoints were all-cause mortality and the combined endpoint of all-cause mortality and cardiovascular events (any event rate). A Cox regression analysis with univariate and multivariate analyses and Kaplan-Meier survival analysis was performed. Results: Follow-up data were available of 384 subjects. Subjects were divided according to high (> 2·0 au, n = 60), intermediate (0·2-2·0 au, n = 274) or low (< 0·2 au, n = 50) ery-apoB. Median follow-up was 1767 days (IQR 1564-2001). In univariate analysis, low ery-apoB was associated with increased all-cause mortality [HR 9·9 (1·2-79·0), P = 0·031] and any event rate [HR 3·4 (95% CI 1·3-8·7), P = 0·012]. In a Cox regression analysis, only a history of CVD was significantly associated with any event rate [HR 3·6 (1·6-8·0), P = 0·002], while low ery-apoB showed a trend [HR 2·4 (0·9-6·4), P = 0·07]. In a subgroup analysis, in subjects with a history of CVD, ery-apoB was significantly associated with all-cause mortality (log rank P = 0·021) and any event rate (log rank P = 0·009). Conclusions: Low ery-apoB is associated with increased mortality and cardiovascular risk, especially in patients with a prior history of CVD. These subjects may benefit from more aggressive secondary prevention treatment.
|Keywords||Cardiovascular disease, Complement receptor 1, Immune adherence, Inflammation, Lipid, Red blood cell|
|Persistent URL||dx.doi.org/10.1111/eci.12728, hdl.handle.net/1765/98248|
|Journal||European Journal of Clinical Investigation|
de Vries, M.A, Van Santen, S, Klop, B, van der Meulen, N, van Vliet, M. (Marjolein), van de Geijn, G.J.M, … Castro Cabezas, M. (2017). Erythrocyte-bound apolipoprotein B in atherosclerosis and mortality. European Journal of Clinical Investigation, 47(4), 289–296. doi:10.1111/eci.12728